CA3047449C - Combination of a protein kinase inhibitor and an additional chemotherapeutic agent - Google Patents
Combination of a protein kinase inhibitor and an additional chemotherapeutic agent Download PDFInfo
- Publication number
- CA3047449C CA3047449C CA3047449A CA3047449A CA3047449C CA 3047449 C CA3047449 C CA 3047449C CA 3047449 A CA3047449 A CA 3047449A CA 3047449 A CA3047449 A CA 3047449A CA 3047449 C CA3047449 C CA 3047449C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- nci
- etoposide
- lung
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436046P | 2016-12-19 | 2016-12-19 | |
| US62/436,046 | 2016-12-19 | ||
| PCT/EP2017/083272 WO2018114776A1 (en) | 2016-12-19 | 2017-12-18 | Combination of a protein kinase inhibitor and an additional chemotherapeutic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3047449A1 CA3047449A1 (en) | 2018-06-28 |
| CA3047449C true CA3047449C (en) | 2023-07-04 |
Family
ID=60915499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3047449A Active CA3047449C (en) | 2016-12-19 | 2017-12-18 | Combination of a protein kinase inhibitor and an additional chemotherapeutic agent |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11246929B2 (enExample) |
| EP (1) | EP3554495B1 (enExample) |
| JP (1) | JP7113826B2 (enExample) |
| KR (1) | KR102607967B1 (enExample) |
| AU (1) | AU2017384134B2 (enExample) |
| CA (1) | CA3047449C (enExample) |
| ES (1) | ES3040063T3 (enExample) |
| WO (1) | WO2018114776A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102013008118A1 (de) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| JP7313492B2 (ja) * | 2019-06-27 | 2023-07-24 | メッドシャイン ディスカバリー インコーポレイテッド | Ｄｎａ－ｐｋ阻害剤としてのキノリン及びシンノリン誘導体 |
| CN116670128A (zh) * | 2020-12-28 | 2023-08-29 | 南京明德新药研发有限公司 | 吗啉取代的苯并嘧啶类化合物的晶型及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8710095B2 (en) | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| CN1861050A (zh) | 2006-06-21 | 2006-11-15 | 山东蓝金生物工程有限公司 | 一种同载铂类化合物及其增效剂的抗癌药物缓释注射剂 |
| BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
| SG188802A1 (en) | 2008-03-06 | 2013-04-30 | Genentech Inc | Combination therapy with c-met and egfr antagonists |
| SG11201406584TA (en) | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
| DE102013008118A1 (de) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| KR102411227B1 (ko) | 2013-10-17 | 2022-06-21 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정 |
-
2017
- 2017-12-18 AU AU2017384134A patent/AU2017384134B2/en active Active
- 2017-12-18 JP JP2019532927A patent/JP7113826B2/ja active Active
- 2017-12-18 CA CA3047449A patent/CA3047449C/en active Active
- 2017-12-18 US US16/462,309 patent/US11246929B2/en active Active
- 2017-12-18 EP EP17823090.0A patent/EP3554495B1/en active Active
- 2017-12-18 WO PCT/EP2017/083272 patent/WO2018114776A1/en not_active Ceased
- 2017-12-18 ES ES17823090T patent/ES3040063T3/es active Active
- 2017-12-18 KR KR1020197020952A patent/KR102607967B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190365896A1 (en) | 2019-12-05 |
| AU2017384134B2 (en) | 2022-03-24 |
| KR102607967B1 (ko) | 2023-11-29 |
| CA3047449A1 (en) | 2018-06-28 |
| JP2020502182A (ja) | 2020-01-23 |
| EP3554495A1 (en) | 2019-10-23 |
| EP3554495B1 (en) | 2025-06-04 |
| ES3040063T3 (en) | 2025-10-28 |
| WO2018114776A1 (en) | 2018-06-28 |
| AU2017384134A1 (en) | 2019-08-01 |
| KR20190099253A (ko) | 2019-08-26 |
| US11246929B2 (en) | 2022-02-15 |
| JP7113826B2 (ja) | 2022-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102713072B1 (ko) | 두경부암 치료를 위한 egfr 저해제 | |
| US20200368235A1 (en) | Ibrutinib combination therapy | |
| JP2016535756A (ja) | ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法 | |
| EP3429614B1 (en) | Method of treating triple negative breast cancer | |
| JP7783217B2 (ja) | アズブジンを含む抗腫瘍医薬組成物 | |
| AU2017384134B2 (en) | Combination of a protein kinase inhibitor and an additional chemotherapeutic agent | |
| JP2020512977A (ja) | Ｃｈｋ１阻害剤とｗｅｅ１阻害剤との組み合わせ | |
| WO2022052874A1 (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
| JP2024531492A (ja) | Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療 | |
| JP2018513185A (ja) | 共結晶組成物及びその医薬用途 | |
| US20190192602A1 (en) | Improved Therapeutic Index of Anti-Immune Checkpoint Inhibitors Using Combination Therapy Comprising A PHY906 Extract, A Scutellaria baicalensis Georgi (S) Extract or A Compound From Such Extracts | |
| KR20250121432A (ko) | Mta-협력 prmt5 저해제를 사용한 암 치료 | |
| WO2020114348A1 (en) | Methods for cancer therapy | |
| CN105476996B (zh) | 姜黄素与阿法替尼联合治疗非小细胞肺癌的用途 | |
| JP2017509671A (ja) | カロリー摂取量減少と協同したがん治療方法で使用されるチロシンキナーゼ阻害剤 | |
| CN113329749A (zh) | 用于治疗葡萄膜黑色素瘤的联合疗法 | |
| CN100475212C (zh) | 用于治疗慢性淋巴细胞白血病的氮芥类似物和甲磺酸依马替尼的组合 | |
| US20190183893A1 (en) | Low dose of sildenafil as an antitumor drug | |
| RU2785997C1 (ru) | Комбинация ингибитора протеинкиназы и дополнительного химиотерапевтического средства | |
| CN110638802A (zh) | Atca在制备治疗肿瘤的药物中的用途 | |
| CN116492320B (zh) | 大果桉醛i在制备肿瘤免疫治疗增效剂中的应用 | |
| US20200397738A1 (en) | Methods for treating cancer and protecting renewable tissues | |
| EP3127544B1 (en) | Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| TW202308641A (zh) | 用於治療癌症之方法及包含cdk抑制劑之給藥方案 | |
| EP4591868A1 (en) | Medicament for preventing and treating tumor and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220921 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241125 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241125 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241125 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251121 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251121 |